Cargando…

Quantitative Relationships between Pulmonary Function and Residual Neuromuscular Blockade

BACKGROUND: Neuromuscular blockade is a risk factor for postoperative respiratory weakness during the immediate postoperative period. The quantitative relationships between postoperative pulmonary-function impairment and residual neuromuscular blockade are unknown. METHODS: 113 patients who underwen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, ShuYing, Lin, WenDong, Zhao, XiNing, Ge, ShengJin, Xue, ZhangGang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832181/
https://www.ncbi.nlm.nih.gov/pubmed/29662906
http://dx.doi.org/10.1155/2018/9491750
Descripción
Sumario:BACKGROUND: Neuromuscular blockade is a risk factor for postoperative respiratory weakness during the immediate postoperative period. The quantitative relationships between postoperative pulmonary-function impairment and residual neuromuscular blockade are unknown. METHODS: 113 patients who underwent elective laparoscopic cholecystectomy were enrolled in this study. They all had a pulmonary-function test (PFT) during the preoperative evaluation. Predictive values based on demographic data were also recorded. The train-of-four ratio (TOFR) was recorded at the same time as the PFT and at every 5 minutes in the qualified 98 patients in the postanesthesia care unit (PACU). We analyzed the degree of PFT recovery when the TOFR had recovered to different degrees. RESULTS: There was a significant difference (P < 0.05) between the preoperative baseline value and the postoperative forced vital capacity at each TOFR point, except at a TOFR value of 1.1. There was also a significant difference (P < 0.05) between the preoperative baseline value and the postoperative peak expiratory flow at each TOFR point. CONCLUSIONS: Postoperative residual neuromuscular blockade was common (75.51%) after tracheal extubation, and pulmonary function could not recover to an acceptable level (85% of baseline value), even if TOFR had recovered to 0.90. TRIAL REGISTRATION: Chinese Clinical Trial Register is ChiCTR-OOC-15005838.